Key risks Market risk: Security markets are volatile and may decline significantly in response to adverse issuer, regulatory, political, or economic developments with different sectors of the market and different security types reacting differently to such developments
Stay tuned as we continue to track the rapidly evolving science on GLP-1s and brain health
Important evidence boundary No formal human clinical trial has ever evaluated IGF-1 LR3 for any therapeutic or performance endpoint
Liraglutide has recently been reported to induce gut microbial structural changes in DIO mice, dominated by changes in the distribution of Proteobacteria and Verrucomicrobia phylotypes without affecting the abundance of Firmicutes 69
Filippini, T., Malavolti, M., Whelton, P
Explore microdosing approaches Some researchers and providers are exploring ultra-low dose GLP-1 medication as a long-term maintenance strategy